Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity
Hideki Iwamoto, Shigeo Shimose, Tomotake Shirono, et al.
Clinical and Molecular Hepatology (2023) Vol. 29, Iss. 3, pp. 593-604
Open Access | Times Cited: 32

Showing 1-25 of 32 citing articles:

Conversion therapy for advanced hepatocellular carcinoma in the era of precision medicine: Current status, challenges and opportunities
Ming‐Da Wang, Xuejun Xu, Ke‐Chun Wang, et al.
Cancer Science (2024) Vol. 115, Iss. 7, pp. 2159-2169
Open Access | Times Cited: 10
Higher objective responses by hepatic arterial infusion chemotherapy following atezolizumab and bevacizumab failure than when used as initial therapy in hepatocellular carcinoma: a retrospective study
Jae-Sung Yoo, Ji Hoon Kim, Hee Sun Cho, et al.
Abdominal Radiology (2024) Vol. 49, Iss. 9, pp. 3127-3135
Closed Access | Times Cited: 4
Transarterial chemoembolization (TACE)-hepatic arterial infusion chemotherapy (HAIC) combined with PD-1 inhibitors plus lenvatinib as a preoperative conversion therapy for nonmetastatic advanced hepatocellular carcinoma: a single center experience
Wenchao Zhao, Che Liu, Yintao Wu, et al.
Translational Cancer Research (2024) Vol. 13, Iss. 5, pp. 2315-2331
Open Access | Times Cited: 4
Conversion Therapy Strategy: A Novel GPC3-Targeted Multimodal Organic Phototheranostics Platform for Mid-late-stage Hepatocellular Carcinoma
Fan Wu, Xin Kuang, Shaocong Deng, et al.
Materials Today Bio (2025) Vol. 30, pp. 101442-101442
Open Access
Efficacy and safety of neoadjuvant therapy for hepatocellular carcinoma with portal vein thrombosis: A meta‑analysis
Wangyi Xuan, Xiao Ming Zhang, Yingying Fang, et al.
Oncology Letters (2025) Vol. 29, Iss. 3
Open Access
HAIC plus lenvatinib and tislelizumab for advanced hepatocellular carcinoma with Vp4 portal vein invasion
Shuang‐Yan Tang, Feng Shi, Yi Xiao, et al.
Hepatology International (2025)
Closed Access
Community characteristics and relationship between gut microbiota and intratumoral microbiota in hepatocellular carcinoma
Hung-Wen Lin, Zhanshan Ma, Jin Li, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access
Anticipation for hepatic arterial infusion chemotherapy in the treatment of hepatocellular carcinoma
Grigorios Christodoulidis, Dimitra Bartzi, Konstantinos Eleftherios Koumarelas
World Journal of Gastrointestinal Oncology (2025) Vol. 17, Iss. 2
Closed Access
SERPINH1 secretion by cancer-associated fibroblasts promotes hepatocellular carcinoma malignancy through SENP3-mediated SP1/SQLE pathway
Hua Xiao, Zhaoying Yao, Tao Li, et al.
International Immunopharmacology (2025) Vol. 150, pp. 114259-114259
Closed Access
Enhanced antitumor activity of combined hepatic arterial infusion chemotherapy with Lenvatinib and PD-1 inhibitors in unresectable hepatocellular carcinoma: a meta-analysis
Lingling Zhao, Cheng Xu, Jiewen Deng, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Adverse events associated with hepatic arterial infusion chemotherapy and its combination therapies in hepatocellular carcinoma: a systematic review
Ying Wu, Zhimin Zeng, Shuanggang Chen, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Neoadjuvant therapy for hepatocellular carcinoma—priming precision innovations to transform HCC treatment
Kristin E. Goodsell, Alice Tao, James O. Park
Frontiers in Surgery (2025) Vol. 12
Open Access
A Metrology Informatics Investigation of Conversion Therapy in Hepatocellular Carcinoma: 2014–2023
Qifeng Chen, Xiongying Jiang, Minshan Chen, et al.
Annals of Surgery Open (2025) Vol. 6, Iss. 1, pp. e562-e562
Open Access
Hepatic arterial infusion chemotherapy combined with lenvatinib and immune checkpoint inhibitor versus lenvatinib for advanced hepatocellular carcinoma: a multicenter study with propensity score and coarsened exact matching
Qunfang Zhou, Huijun Li, Liang Ye, et al.
La radiologia medica (2025)
Open Access
Future perspectives on immunotherapy for hepatocellular carcinoma
Landon L. Chan, Stephen L. Chan
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access
Novel multimodal analgesic regimen for perioperative pain management after hepatic artery infusion chemotherapy in patients with advanced hepatocellular carcinoma
Jing Yan, Rui An, Jingjing Wang, et al.
World Journal of Gastrointestinal Surgery (2025) Vol. 17, Iss. 4
Closed Access
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Japanese perspective
Hironori Koga, Hideki Iwamoto, Hiroyuki Suzuki, et al.
Clinical and Molecular Hepatology (2023) Vol. 29, Iss. 2, pp. 242-251
Open Access | Times Cited: 11
Efficacy and safety of hepatic artery infusion chemotherapy combined with tyrosine kinase inhibitors plus programmed death-1 inhibitors for hepatocellular carcinoma refractory to transarterial chemoembolization
Long-Wang Lin, Kun Ke, Leye Yan, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 11
Mechanism study of oleanolic acid derivative, K73-03, inducing cell apoptosis in hepatocellular carcinoma
Jiaqi Wang, Chuchu Ma, Zhongyuan Tang, et al.
Cancer Cell International (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 3
New insights into mechanisms and interventions of locoregional therapies for hepatocellular carcinoma
Hanyuan Liu, Chunmei Wang, Ruiqiang Wang, et al.
Chinese Journal of Cancer Research (2024) Vol. 36, Iss. 2, pp. 167-194
Open Access | Times Cited: 3
Combining Liver-Directed and Immunotherapy in Advanced Hepatocellular Carcinoma: A Review and Future Directions
Pranav Kumar, Chase J. Wehrle, Keyue Sun, et al.
Surgical Oncology Insight (2024), pp. 100100-100100
Open Access | Times Cited: 3
The immune inductive role of hepatic arterial infusion chemotherapy prior to atezolizumab plus bevacizumab combination therapy in hepatocellular carcinoma
Hiroyuki Suzuki, Miwa Sakai, Hideki Iwamoto, et al.
Gastro Hep Advances (2024) Vol. 3, Iss. 4, pp. 506-509
Open Access | Times Cited: 1
Consistent efficacy of hepatic artery infusion chemotherapy irrespective of PD‑L1 positivity in unresectable hepatocellular carcinoma
Ji Hong Kim, Young Il Kim, Heechul Nam, et al.
Oncology Letters (2024) Vol. 28, Iss. 2
Open Access | Times Cited: 1
Clinical features and prognostic factors of patients with inoperable hepatocellular carcinoma treated with chemotherapy: a population-based study
Yang Gao, Yihang Xu, Yong Wang, et al.
Journal of Gastrointestinal Oncology (2024) Vol. 15, Iss. 3, pp. 1122-1140
Open Access | Times Cited: 1
Case Report: Clinical application of continuous arterial infusion chemotherapy in neoadjuvant therapy for locally advanced gastric cancer
Wenli Lin, Zhong‐Xian Huang, Zhenhua Du, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top